Katarzyna Drzewicka

PhD obtained in 2018 in the lab of Frauke Melchior, where she worked on sumoylation enzymes and gained expertise in molecular biology and post-translational modifications. Following her PhD, she joined Molecure SA, transitioning into drug discovery as a biochemist and later advancing to project and group leader roles. In these positions, she focused on implementing molecular and cellular methods to screen small-molecule compounds. She was actively involved in the chitinase program and currently serves as lead biologist in the early-stage USP21 inhibitor program.